1. 47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM). (December 2022) Authors: Kocoglu, M.H.; Asch, A.; Ramakrishnan, A.; Bachier, C.; Martin, T.; Rodriguez, T.; McArthur, K.; Martin, C.; Namini, H.; Ostertag, E.; Spear, M.; Christie, E.; Belani, R.; Zhang, M.; Cranert, S.; Coronella, J.; Shedlock, D.; Costello, C. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗